Kronos Bio Balance Sheet Health
Financial Health criteria checks 6/6
Kronos Bio has a total shareholder equity of $111.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $150.0M and $38.9M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$124.86m |
| Equity | US$111.13m |
| Total liabilities | US$38.90m |
| Total assets | US$150.02m |
Recent financial health updates
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?
Jun 11
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?
Jan 19We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate
Aug 21We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully
Feb 22Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?
Nov 01Recent updates
Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being
Jun 20Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?
Jun 11Kronos Bio: Still Promising But Riskier Following ASCO Update
Jun 05Kronos Bio: Underestimated Drug Discovery Platform
May 06Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?
Jan 19We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate
Aug 21We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully
Feb 22Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?
Nov 01Kronos Bio, Invivoscribe to develop companion diagnostic for leukemia drug entospletinib
Aug 16Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?
Jul 07We're Hopeful That Kronos Bio (NASDAQ:KRON) Will Use Its Cash Wisely
Feb 01How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?
Mar 03Read This Before Selling Kronos Bio, Inc. (NASDAQ:KRON) Shares
Jan 09
Kronos Bio EPS misses by $4.10
Nov 18Financial Position Analysis
Short Term Liabilities: KRON's short term assets ($127.9M) exceed its short term liabilities ($15.4M).
Long Term Liabilities: KRON's short term assets ($127.9M) exceed its long term liabilities ($23.5M).
Debt to Equity History and Analysis
Debt Level: KRON is debt free.
Reducing Debt: KRON had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KRON has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: KRON has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 20.3% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 06:31 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kronos Bio, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhiqiang Shu | Berenberg |
| Robert Burns | H.C. Wainwright & Co. |
| Michael Yee | Jefferies LLC |